SGLT-2 inhibitors in heart failure and chronic kidney disease: A review for internists.

IF 3.4 4区医学 Q1 MEDICINE, GENERAL & INTERNAL

Cleveland Clinic Journal of Medicine Pub Date : 2024-07-01 DOI:10.3949/ccjm.91a.23093

Rahul Jaswaney, Samantha Sokoloff, Val Rakita, Daniel J Rubin

引用次数: 0

Abstract

Despite current therapies, heart failure and chronic kidney disease continue to be major causes of morbidity and mortality. Sodium-glucose cotransporter 2 (SGLT-2) inhibitors have recently become standard-of-care therapy for these conditions. This review summarizes important randomized controlled trials of SGLT-2 inhibitors and guidelines for using these agents in patients with heart failure and chronic kidney disease in both clinic and hospital settings.

查看原文本刊更多论文

SGLT-2 抑制剂在心力衰竭和慢性肾病中的应用：内科医生综述。

尽管目前有各种疗法，但心力衰竭和慢性肾病仍然是发病和死亡的主要原因。钠-葡萄糖共转运体 2（SGLT-2）抑制剂最近已成为治疗这些疾病的标准疗法。本综述总结了 SGLT-2 抑制剂的重要随机对照试验，以及在临床和医院环境中对心力衰竭和慢性肾病患者使用这些药物的指南。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cleveland Clinic Journal of Medicine 医学-医学：内科

CiteScore

3.80

自引率

0.00%

发文量

109

审稿时长

6-12 weeks

期刊介绍： The mission of Cleveland Clinic Journal of Medicine (CCJM) is to provide its readers with up-to-date, practical, clinical information relevant to internal medicine, cardiology, and related fields. Consistent with this mission, CCJM focuses on timely review articles and other content that has a continuing-education orientation rather than on original research or case reports. CCJM authors, drawn from Cleveland Clinic and other top medical institutions throughout the world, are asked to identify new findings that are changing the practice of medicine and to advise readers how to apply them in daily patient care. Authors are chosen for their experience, acquired through caring for patients, teaching other physicians, and researching clinical questions.